<DOC>
	<DOCNO>NCT00225290</DOCNO>
	<brief_summary>To compare overall survival thalidomide- placebo-treated advanced HCC patient .</brief_summary>
	<brief_title>Phase III Trial Oral Thalidomide Advanced Hepatocellular Carcinoma With Poor Liver Reserve</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Patients measurable , metastatic locally advanced hepatocellular carcinoma 2 . The diagnosis HCC establish either cyto/histology 3 . Patients must &gt; 20 year age . 4 . ECOG score &lt; 2 . 5 . Signed informed consent . 6 . Female patient childbearing age must negative pregnancy test . 1 . Patients systemic disease require concurrent usage glucocorticosteroid immunosuppressant agent ( ) eligible . 2 . Patients advanced second primary malignancy eligible . 3 . Patients active infection eligible . 4 . Patients pregnancy breastfeed eligible . 5 . Patients brain metastasis eligible .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Phase III</keyword>
	<keyword>Hepatocellular Carcinoma</keyword>
</DOC>